This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the IRAK4 degrader KT-474/SAR444656 from Kymera/Sanofi and the potential in HS (Hidradenitis suppurativa) and AD (atopic dermatitis)

Ticker(s): KYMR, REGN, LLY, SNY, ABBV

Who's the expert?

Institution: Indiana University School of Medicine

  • Chair and associate professor of dermatlogy at Indiana University School of Medicine.
  • Currently manages 100 patients with vitligo.
  • Previously served as Vice-Chair for Research and Education at Tufts Medical Center, focusing on clinical trials for inflammatory disorders of the skin.

Interview Goal
Discuss potential of IRAK4 degrader in HS or AD

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.